RevnaBio Secures Triple International Laboratory Accreditation to Expand Precision Medicine and Clinical Research Infrastructure in Africa

Key Takeaways

• Triple A2LA accreditation covers labs, biobanking, proficiency testing.
• Enables local molecular diagnostics, reducing overseas sample shipments.
• Provides accredited proficiency testing for West African laboratory networks.
• Supports pharma research with high‑quality African genomic data.
• Strengthens Africa’s role in global precision‑medicine initiatives.

Summary

RevnaBio received triple accreditation from the American Association for Laboratory Accreditation (A2LA) for ISO 15189, ISO 20387 and ISO/IEC 17043, validating its medical laboratory, biobanking and proficiency‑testing operations. The certifications boost diagnostic quality, enable local molecular testing, and provide a trusted platform for pharmaceutical and research partners across Africa. This milestone marks a major step in expanding precision‑medicine infrastructure in West Africa and improving patient outcomes. RevnaBio can now offer accredited proficiency‑testing programs to regional laboratories.

Pulse Analysis

Receiving A2LA’s triple accreditation places RevnaBio among a small group of facilities that meet ISO 15189, ISO 20387 and ISO/IEC 17043 simultaneously. ISO 15189 guarantees that the medical laboratory adheres to rigorous quality‑management and competence criteria, essential for reliable molecular and genomic testing. ISO 20387 confirms that the biobank follows internationally accepted governance, traceability and storage protocols, while ISO/IEC 17043 authorizes the design of accredited proficiency‑testing schemes. Together, these standards elevate the credibility of RevnaBio’s results, giving clinicians and patients confidence in locally performed diagnostics that previously required overseas referral.

The accreditation also unlocks new avenues for biomedical research across the continent. With a certified biobanking system, RevnaBio can supply research‑grade specimens linked to high‑quality clinical data, a prerequisite for robust biomarker discovery and pharmacogenomic studies. Global pharmaceutical companies and diagnostics developers now have a vetted partner for African cohort trials, ensuring regulatory compliance and data integrity. By anchoring these capabilities in Ghana, the company helps close the representation gap in drug development, allowing therapies to be evaluated against the genetic diversity of African populations.

From a market perspective, RevnaBio’s expanded service portfolio strengthens the emerging precision‑medicine ecosystem in West Africa. Accredited proficiency‑testing programs will raise the baseline performance of regional laboratories, fostering a culture of continuous improvement and enabling participation in international quality‑assessment networks. Investors and policymakers see the triple accreditation as a signal of scalable, high‑impact health infrastructure, likely spurring further public‑private partnerships and funding for similar initiatives. As the continent’s demand for advanced diagnostics grows, RevnaBio is positioned to become a central hub for data generation, clinical trials, and therapeutic innovation.